Cas:957261-62-0 1-[(3-methoxyphenyl)methyl]pyrazol-4-amine manufacturer & supplier

Chemical Name:1-[(3-methoxyphenyl)methyl]pyrazol-4-amine

CAS.NO:957261-62-0

Synonyms:1-[(3-methoxyphenyl)methyl]pyrazol-4-amine

Molecular Formula:C₁₁H₁₃N₃O

Molecular Weight:203.24000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:53.07000

Exact Mass:203.10600

LogP:2.10340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-[(3-methoxyphenyl)methyl]pyrazol-4-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-[(3-methoxyphenyl)methyl]pyrazol-4-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-[(3-methoxyphenyl)methyl]pyrazol-4-amine Use and application,1-[(3-methoxyphenyl)methyl]pyrazol-4-amine technical grade,usp/ep/jp grade.

Related News: Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. 1-[(3-methoxyphenyl)methyl]pyrazol-4-amine manufacturer The victim — who died Saturday — was a 44-year-Chinese man who flew in from Wuhan in January. 1-[(3-methoxyphenyl)methyl]pyrazol-4-amine supplier We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� 1-[(3-methoxyphenyl)methyl]pyrazol-4-amine vendor Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. 1-[(3-methoxyphenyl)methyl]pyrazol-4-amine factory In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.